Last week, Wall Street slammed Poniard Pharmaceuticals Inc. after the company disclosed apparently good news: an endpoint met in the Phase II trial with picoplatin in metastatic colorectal cancer. It was anything but the first time that the wider world reflexively failed - at least from the company's point of view - to understand and appreciate study data. Read More
